Korea Research Institute of Bioscience and Biotechnology

Y-biologics Inc.

Industry-academic Cooperation Foundation, the Catholic University of Korea

Kyu Won Cho

Young Woo Park

Ki Won Jo

Eun Kyung Lee

Jung Jae Yu

Ji Hyun Park

Seok Ho Yoo

Dong Jin Kim

Mi Kyung Park

Myeoung Hee Jang

Ho Youn Kim

Mi La Cho

Hye Nan Kim

Jun Geol Ryu

Jin Sil Park

Srok Ho Yoo

Yun Jung Park

Sun-Ha Yoon

Chan Woong Park

Yun Ju Woo

Seon Ha Yun

Eun Jung Song

Jae Kyeong Byun

Hye Jwa Oh

Soon Sil Hyun

Mi Ra Park

Jin Mi Oh

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Anti-c-Met antibody having HGF activity and use thereof

The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

Pharmaceutical composition containing an endocytic motif and protein transduction domains for preventing or treating cancer

The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-&#x3b1; and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.

TNF-A and TWEAK dual antagonist for the prophylaxis and treatment of autoimmune diseases

Growing community of inventors

Daejeon, South Korea

Kyu Won Cho